BLRX Share Price Performance
₪0.022
-0.14 (-86.16%)
Price ₪0.022
Share Price₪0.022
BLRX Community Narratives
There are no narratives available yet.
Recent BLRX News & Updates
No updates
BioLineRx Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 14, 2025
- Earnings per share (EPS)
- -0.0013
- Gross Margin
- 64.90%
- Net Profit Margin
- -15.21%
- Debt/Equity Ratio
- 59.0%
BioLineRx Ltd. Competitors
About BLRX
- Founded
- 2003
- Employees
- 28
- CEO
- WebsiteView website
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Israeli Market Performance
- 7 Days: -3.9%
- 3 Months: 11.8%
- 1 Year: 56.1%
- Year to Date: 23.8%
Over the last 7 days, the market has dropped 3.9%, driven by pullbacks in every sector, especially the Financials sector. As for the longer term, the market has actually risen by 56% in the last year. Looking forward, earnings are forecast to grow by 18% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading